Walid Eltaraboulsi, MD
Pulmonary Disease · Charlotte, NCNPI 1245491083
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 57.8% of the total. Reporting peaked in 2024 at $5,490 and has fallen 68.9% since, to $1,708 in 2025.
Across 256 payments — averaging $42.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- AstraZeneca$1K
- GSK$1K
- Amgen$314
- Sanofi$290
- Mylan Specialty L.p.$214
- plus $2K from 29 others
Across 55 payments — averaging $4290.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$66K
- Chiesi USA, Inc.$39K
- Astrazeneca UK Limited$38K
- Novartis$26K
- Sanofi$22K
- Insmed, Inc.$21K
- plus $24K from 2 others
What the payments were for
- Travel & lodging$2,07219%
- Food & beverage$4,71243%
- Education$4,07037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $6,271 |
| AstraZeneca | 50 | $1,067 |
| GSK | 56 | $1,051 |
| Amgen | 22 | $314 |
| Sanofi | 13 | $290 |
| Mylan Specialty L.p. | 14 | $214 |
| Grifols USA, LLC | 18 | $193 |
| Insmed, Inc. | 9 | $192 |
| Johnson & Johnson | 10 | $191 |
| Boehringer Ingelheim | 7 | $188 |
| Abbott | 6 | $134 |
| Regeneron Healthcare Solutions, Inc. | 4 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $58 |
| ANI Pharmaceuticals, Inc. | 3 | $51 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Philips North America LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Novo Nordisk | 3 | $41 |
| Novartis | 2 | $34 |
| Circassia Inc. | 2 | $31 |
| Masimo Corporation | 1 | $29 |
| Inogen, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Verona Pharma, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Pfizer | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Cvrx, Inc. | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Breathe Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,169
- NUCALA$120
How this compares
$10,854 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,175 | $1,096,442 |
| OfevNintedanib Esylate | 35 | $406,695 |
| Breo ElliptaFluticasone/Vilanterol | 440 | $255,397 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 298 | $197,012 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $125,403 |
| Dupixent PenDupilumab | 19 | $71,570 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 73 | $64,530 |
| EliquisApixaban | 62 | $48,130 |
| Spiriva RespimatTiotropium Bromide | 49 | $45,671 |
| SymbicortBudesonide/Formoterol Fumarate | 116 | $43,498 |
| Spiriva HandihalerTiotropium Bromide | 29 | $31,002 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 43 | $27,456 |
| Arnuity ElliptaFluticasone Furoate | 77 | $24,458 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 870 | $24,012 |
| Advair HfaFluticasone Propion/Salmeterol | 39 | $15,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,051 | $1,579,9352,006 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $188 | $526,121173 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,067 | $196,358294 claims |
| PfizerEliquis | $19 | $48,13062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Charlotte
- Jaspal SinghCharlotte$191K
- Selwyn SpangenthalCharlotte$70K
- Muhammad RashadCharlotte$14K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.